Fred Alger Management Inc. lessened its stake in TESARO Inc (NASDAQ:TSRO) by 67.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,217 shares of the biopharmaceutical company’s stock after selling 187,786 shares during the period. Fred Alger Management Inc. owned 0.17% of TESARO worth $7,642,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently bought and sold shares of the company. Exane Derivatives grew its stake in TESARO by 137.1% in the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 1,123 shares during the last quarter. Toronto Dominion Bank grew its stake in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,130 shares during the last quarter. Bourgeon Capital Management LLC purchased a new position in TESARO in the fourth quarter valued at about $211,000. Fox Run Management L.L.C. purchased a new stake in shares of TESARO during the fourth quarter worth about $218,000. Finally, Commonwealth Equity Services Inc purchased a new stake in shares of TESARO during the third quarter worth about $222,000.
In other TESARO news, VP Grant C. Bogle sold 1,809 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $54.85, for a total value of $99,223.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Orlando Oliveira sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $69.88, for a total value of $209,640.00. Following the completion of the transaction, the senior vice president now directly owns 9,076 shares of the company’s stock, valued at $634,230.88. The disclosure for this sale can be found here. Over the last three months, insiders acquired 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. Insiders own 34.60% of the company’s stock.
TESARO Inc (NASDAQ TSRO) opened at $68.12 on Monday. TESARO Inc has a twelve month low of $52.20 and a twelve month high of $176.04. The company has a quick ratio of 4.39, a current ratio of 4.74 and a debt-to-equity ratio of 1.75.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. The company had revenue of $48.02 million during the quarter, compared to analyst estimates of $51.78 million. equities research analysts anticipate that TESARO Inc will post -9.54 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Fred Alger Management Inc. Has $7.64 Million Holdings in TESARO Inc (TSRO)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/12/fred-alger-management-inc-has-7-64-million-holdings-in-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.